Immuron Limited
NASDAQ: IMRN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven George Lydeamore
- Employees
- 7
- Headquarters
- Carlton, Australia
- IPO year
- 2017
- Market cap
- $7.0M
- Website
- https://www.immuron.com.au
Loading IMRN…
Loading profile data…Frequently asked questions about IMRN
What does Immuron Limited (IMRN) do?
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Cur...
Where does IMRN trade?
Immuron Limited (IMRN) trades on the NASDAQ Capital Market.
What sector is IMRN in?
Immuron Limited (IMRN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immuron Limited?
Steven George Lydeamore is the chief executive officer of Immuron Limited (IMRN).
Where is Immuron Limited headquartered?
Immuron Limited is headquartered in Australia.
Does IMRN pay a dividend?
Immuron Limited (IMRN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMRN go public?
Immuron Limited (IMRN) completed its initial public offering in 2017.
Is IMRN an ADR?
Yes — IMRN is an American Depositary Receipt; its underlying shares trade on a non-US exchange. Immuron Limited reporting and dividends follow the underlying issuer.